GEF-B vs TSLA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GEF-B presents a conflicting profile characterized by a weak Piotroski F-Score of 3/9, indicating deteriorating fundamental health. While the stock has shown strong 1-year price momentum (+50.2%), this is decoupled from a concerning decline in revenue (-29.8% Q/Q) and a dangerously high dividend payout ratio of 88.98%. The current price of $83.34 sits between the defensive Graham Number ($65.38) and the growth-based Intrinsic Value ($107.08), suggesting a valuation that is currently pricing in growth that the revenue data does not support.
Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.
Compare Another Pair
Related Comparisons
GEF-B vs TSLA: Head-to-Head Comparison
This page compares Greif, Inc. (GEF-B) and Tesla, Inc. (TSLA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.